Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2004-10, Vol.46 (1), p.113-118
• Main Authors: Hirsh, Vera, Whittom, R., Desjardins, P., Laberge, F., Latreille, J., Samson, B., Langleben, A.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Chemonaı̈ve; Days 1 and 8 administration; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lower toxicity; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Medical sciences; Metastatic; Middle Aged; Neoplasm Metastasis; Non-small cell lung carcinoma; Phase II study; Pneumology; Survival Analysis; Taxoids - administration & dosage; Tumors of the respiratory system and mediastinum
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2004.03.007

Docetaxel and Gemcitabine are active agents in non-small cell lung carcinoma (NSCLC). They have different mechanism of action, minimal overlapping toxicity, and are easily administered on an outpatient basis. This phase II study evaluated Docetaxel administered with Gemcitabine on days 1 and 8 in a 3-week cycle, to determine its efficacy, while attempting to lower the regimen’s toxicity, especially myelosuppression which can occur when Docetaxel is administered at full dose on day 1 only. Forty-three chemonaive patients, 40 evaluable, were entered in this trial between May 2001 and March 2002. Thirty-seven patients had stage IV and three patients had stage III B NSCLC, median age 58 (ages 32–78), median performance status (PS) 1 (range 0–2). They were treated with Docetaxel 36 mg/m 2 and Gemcitabine 1000 mg/m 2 intravenously on days 1 and 8 in a 3-week cycle. No growth factors were administered. Of 40 evaluable patients, 4 achieved partial response (10%), 25 stable disease (62.5%) and 11 progressive disease (27.5%). Median time-to-disease progression was 15 weeks. Median survival was 7.75 months. One year survival was 32.5% (13 patients). Hematologic toxicity was minimal, non-hematologic toxicity was easily treatable. Docetaxel, when given with Gemcitabine on days 1 and 8 every 3 weeks, is less myelotoxic, yet still an effective treatment for metastatic NSCLC.